Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
43.94USD
14 Dec 2018
43.94USD
14 Dec 2018
Change (% chg)
$0.83 (+1.93%)
$0.83 (+1.93%)
Prev Close
$43.11
$43.11
Open
$42.87
$42.87
Day's High
$44.41
$44.41
Day's Low
$42.87
$42.87
Volume
78,261
78,261
Avg. Vol
100,964
100,964
52-wk High
$85.66
$85.66
52-wk Low
$42.87
$42.87
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 51.34 | 0.907 |
| Jun '18 | 59.30 | 0.172 | |
| Mar '18 | 46.63 | 0.169 | |
| FY 2017 | Dec '17 | 46.78 | 0.801 |
| Sep '17 | 63.02 | 0.979 | |
| Jun '17 | 50.11 | 0.280 | |
| Mar '17 | 76.79 | 1.418 | |
| FY 2016 | Dec '16 | 81.14 | 3.530 |
| Sep '16 | 37.83 | 0.727 | |
| Jun '16 | 40.92 | 0.796 | |
| Mar '16 | 29.59 | -0.057 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 5 | 54.17 | 58.30 | 49.90 | 55.10 |
| Quarter Ending Mar-19 | 3 | 55.60 | 58.70 | 52.90 | -- |
| Year Ending Dec-18 | 5 | 211.43 | 215.50 | 207.20 | 214.60 |
| Year Ending Dec-19 | 5 | 231.63 | 250.54 | 218.60 | 247.57 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 4 | 1.18 | 1.34 | 0.85 | 1.18 |
| Quarter Ending Mar-19 | 2 | 1.05 | 1.16 | 0.94 | -- |
| Year Ending Dec-18 | 4 | 3.83 | 3.99 | 3.51 | 4.37 |
| Year Ending Dec-19 | 5 | 4.61 | 5.45 | 3.74 | 5.04 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 9.78 | 31.13 | 34.39 | |
| P/E High - Last 5 Yrs. | -- | 40.59 | 46.24 | |
| P/E Low - Last 5 Yrs. | -- | 23.99 | 24.59 | |
| Beta | 1.23 | 0.91 | 0.91 | |
| Price to Sales (TTM) | 3.59 | 4.00 | 6.22 | |
| Price to Book (MRQ) | 5.34 | 5.02 | 5.20 | |
| Price to Tangible Book (MRQ) | 9.43 | 5.76 | 6.74 | |
| Price to Cash Flow (TTM) | 8.87 | 23.20 | 24.17 | |
| % Owned Institutions | -- | 0.95 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.55 | 1.44 | |
| Dividend Yield - 5 Year Avg | -- | 1.56 | 1.46 | |
| Dividend 5 Year Growth Rate | -- | 4.21 | 4.94 | |
| Payout Ratio(TTM) | 0.00 | 45.68 | 42.49 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 22.46 | 2.33 | 8.17 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 160.39 | 4.80 | 6.50 | |
| Sales - 5 Yr. Growth Rate | -- | 10.00 | 10.44 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -64.84 | 17.26 | 23.09 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 3,637.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.88 | 10.49 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.23 | 14.59 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 3.76 | 2.20 | 2.28 |
| Current Ratio (MRQ) | 3.88 | 3.02 | 3.10 |
| LT Debt to Equity (MRQ) | 0.00 | 8.89 | 11.49 |
| Total Debt to Equity (MRQ) | 0.00 | 12.69 | 16.03 |
| Interest Coverage (TTM) | -- | 35.18 | 30.57 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 75.17 | 54.41 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.86 | 52.36 | |
| EBITD Margin (TTM) | 33.38 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.41 | 13.16 | |
| Operating Margin (TTM) | 32.21 | 14.42 | 6.07 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.55 | 8.47 | |
| Pre-Tax Margin (TTM) | 32.20 | 14.96 | 7.02 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.97 | 8.71 | |
| Net Profit Margin (TTM) | 39.32 | 11.16 | 3.12 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.23 | 4.91 | |
| Effective Tax Rate (TTM) | -22.12 | 23.45 | 23.26 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.65 | 23.83 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 3,193,182 | 997,011,333 | 873,051,409 | |
| Net Income/Employee (TTM) | 1,255,584 | 118,232,370 | 103,483,755 | |
| Receivable Turnover (TTM) | 4.67 | 5.82 | 5.80 | |
| Inventory Turnover (TTM) | 12.27 | 2.68 | 3.56 | |
| Asset Turnover (TTM) | 1.33 | 0.99 | 0.95 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 52.32 | 11.98 | 11.45 | |
| Return on Assets - 5 Yr. Avg. | -- | 13.28 | 12.50 | |
| Return on Investment (TTM) | 64.07 | 15.55 | 14.96 | |
| Return on Investment - 5 Yr. Avg. | -- | 17.28 | 16.23 | |
| Return on Equity (TTM) | 70.78 | 16.92 | 16.52 | |
| Return on Equity - 5 Yr. Avg. | -- | 18.21 | 17.37 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 186.11 | -- | -- |
| EPS (TTM) % | 3,033.35 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eagle Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -1.54 | -4.93 | 29 | 20 |
| 13 Week | -28.91 | -32.37 | 9 | 34 |
| 26 Week | -33.14 | -38.22 | 12 | 28 |
| 52 Week | -9.55 | -23.34 | 38 | 12 |
| YTD | -26.58 | -35.52 | 17 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 258 |
| Total Shares Held: | 15,718,356 |
| 3 Mo. Net Change: | -72,673 |
| # New Positions: | 30 |
| # Closed Positions: | 24 |
| # Increased Positions: | 131 |
| # Reduced Positions: | 80 |
| # Net Buyers: | 51 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.